We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

BIOBASE's Softwares Achieve Affymetrix GeneChip Compatibility

Read time: Less than a minute

BIOBASE announced that it has joined the Affymetrix GeneChip-compatible Applications Program, and its ExPlain™ Analysis System and TRANSFAC® database has achieved GeneChip-compatible™ status with the Affymetrix Inc. GeneChip® microarray platform.

As a GeneChip-compatible software provider, BIOBASE is committed to seamlessly integrating its applications with the Affymetrix GeneChip platform.

BIOBASE’s award winning ExPlain™ Analysis System provides a fully integrated analysis pipeline for explaining biology on the levels of transcription regulation and pathway analysis.

In addition, TRANSFAC® provides data on transcription factors, their experimentally-proven binding sites, and regulated genes. Both products offer the ability to analyze high throughput experimental data such as Affymetrix microarrays for the identification of future research targets.

According to Holger Karas, Senior Vice President of Business Development, “Combining the vast repository of information available in our products with Affymetrix and the GeneChip-compatible Applications Program offers our customers an unparalleled opportunity to advance their current research and quickly develop experimental direction for future study.”

“Affymetrix is pleased to welcome BIOBASE to the family of GeneChip-compatible software providers,” said Steve Lincoln, vice president of Informatics at Affymetrix. "The coupling of the rich content of TRANSFAC with the analytical methods in ExPlain can result in a greater understanding of disease states and their associated biological processes to users of GeneChip microarrays."